Organic Active Ingredients TRIZ Cases

Crystalline tartrate salt of structure I stabilizes efficacy against resistant solid tumors and hematopoietic cancers.

Combines a PI3Kδ selective inhibitor with an anti-CD20 antibody to target B-cell proliferation pathways.

Hydrangenol inhibits MMP-1 production while increasing hyaluronic acid levels, preventing UV-induced collagen degradation.

Formula I compounds inhibit PARP7 to treat cancer without off-target toxicity.

Formula IB compound inhibits K-Ras activity across multiple mutant variants, addressing the need for broader therapeutic options in cancer treatment.

Progesterone administration induces ovulation via LH surge, avoiding ovarian hyperstimulation syndrome and reducing treatment costs.

Antisense oligonucleotides reduce Synaptogyrin-3 expression to mitigate vesicle mobility defects in tauopathies.

Segmentation and local quality principles guide the design of brain-penetrant compounds that inhibit HDAC6 while sparing other paralogs, reducing side effects.

Coacervation forms drug coacervates inducing lipid bilayers to lower lipid-to-drug ratios, avoiding saturation effects in pulmonary delivery.

Intrathecal double-stranded RNA reaches central nervous system tissues to inhibit target gene expression without external carriers.

Benzothiazole compounds activate SUMO1 to increase SERCA2a stability, resolving the complexity of gene delivery therapies.

Merges three distinct therapeutic agents to enhance anti-tumor efficacy while managing treatment complexity through coordinated administration protocols.

Fused heterocyclic compounds bind SOS1 to block Ras activation, addressing the lack of direct Ras inhibitors for cancer therapy.

Carbon glycoside linkages resist metabolic degradation to maintain therapeutic effectiveness against diabetes and viral infections without drug resistance.

Heparin-protamine iron nanoparticles reduce labeling time while maintaining cell viability through composite structures.

Melatonin and erythropoietin mitigate inflammatory responses and restore neural integrity in infants suffering from prenatal opioid exposure.

Pressure-sensitive adhesive matrix patch delivers antifungal agents through skin to infected nail tissue.

A heteroaromatic macrocyclic ether compound inhibits ROS1 and ALK signaling pathways to treat solid tumors.

A dietary composition for cats combines arachidonic acid with botanical ingredients to lower circulating pro-inflammatory cytokines.

Light-regulated proteolysis targeting chimeric molecules resolve excessive ABL degradation by enabling precise temporal control over BCR-ABL expression levels.

Inhaled diketopiperazine treprostinil resolves pulmonary arterial hypertension stability and compliance trade-offs.

Radiofrequency energy induces mechanical tumbling in iron oxide core nanoparticles to achieve uniform drug release across tumor volumes without hyperthermia.

A tapentadol tablet uses a lipid glyceride matrix to control drug release rates without polymers.

Guide nucleic acid and editor protein target blood coagulation inhibitory genes to regulate the clotting system.

Ciclopirox enhances uroporphyrinogen III synthase stability and catalytic activity to manage congenital erythropoietic porphyria.

Lyoprotectants stabilize the formulation, enabling rapid reconstitution and mechanical integrity without phase separation.

Compound A monocitrate monohydrate salt prevents solvate formation to ensure stability and solubility.

Polyacrylamide nanogels extend pharmacokinetics and reduce side effects by releasing chelators upon redox triggers.

A multifunctional nucleic-acid-based anticancer drug chemically binds gold nanoparticles and an anticancer drug to a linear nucleic acid with a thiol group at the 5′ end.

Low pKa acid additives prevent molecular weight reduction and impurity formation in polymer drug delivery systems.

Naphthalenesulfonamide compounds reduce polar surface area to improve membrane permeation while maintaining high binding affinity to Keap1.

Modified nucleosides extend therapeutic duration and reduce side effects, resolving the trade-off between consistent symptom relief and molecular complexity.

Replacing depleted microRNAs in ependymal cells restores ciliary beating frequency and reduces ventricular enlargement associated with schizophrenia.

Naphthyridine compounds act as positive allosteric modulators for the GABAA alpha 5 receptor.

Formula I compounds selectively modulate NR2C subunits, reducing sedation and hallucinations while treating cognitive impairments.

A PUFA coating on titanium implants uses UV irradiation to induce photo-oxidation and stable chemical bonding.

Optimized dsRNAs inhibit PCSK9 expression while minimizing cytotoxicity for hypercholesterolemia treatment.

Quantifying microRNA levels in test samples against controls enables accurate diagnosis of myeloproliferative disorders.

Dasatinib cyclamic and tosylate salts improve aqueous solubility while maintaining chemical stability.